- Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Monday, June 12, 2017
==Gilead Sciences (GILD) : submits a NDA for HIV Treatment
Gilead Sciences submits a NDA to the FDA for an investigational, once-daily single tablet regimen containing bictegravir and emtricitabine/tenofovir alafenamide for the treatment of HIV-1 in adults
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment